Business Context and Reporting Period
This Form 8-K, filed on August 21, 2024, reports that Rafael Holdings, Inc. ("Rafael") entered into an Agreement and Plan of Merger with Cyclo Therapeutics, Inc. ("Cyclo"). The transaction involves a business combination where Cyclo will become a wholly-owned subsidiary of Rafael. The filing also discloses a new convertible note agreement between the two entities.
Key Financial Metrics and Transaction Terms
- Valuation: Cyclo shares are valued at $0.95 per share for the purpose of the exchange ratio.
- Consideration: Cyclo equity holders will receive Rafael Class B Common Stock. Options and warrants will convert to Rafael equivalents.
- Debt Instrument: Rafael entered into a Second Amended and Restated Note Purchase Agreement with Cyclo, purchasing a convertible promissory note with a principal amount of $3,000,000.
- Liquidity Support: Rafael agreed to fund Cyclo's operations and debt obligations until the earlier of the closing or termination of the agreement, contingent on Cyclo operating in the ordinary course.
- Financial Reporting: The filing does not provide specific revenue, profit, cash flow, or margin data for either company.
Material Changes and Transaction Structure
The primary material change is the execution of the Merger Agreement. The transaction structure involves two steps: (1) First Merger Sub merges with Cyclo, making Cyclo a subsidiary of Rafael; and (2) Cyclo merges into Second Merger Sub, which becomes the surviving entity. Rafael's existing capital stock remains outstanding, with new Class B shares issued to Cyclo holders. Rafael has agreed to appoint Markus W. Sieger, a current Cyclo director, to the Rafael board.
Guidance, Outlook, and Risks
- Timeline: The Business Combination is expected to close in the fourth calendar quarter of 2024, subject to stockholder approvals and other conditions.
- Conditions Precedent: Closing requires approval from both Rafael and Cyclo stockholders, effectiveness of a Form S-4 registration statement, and listing of Rafael Class B Common Stock on the New York Stock Exchange.
- Termination Rights: The agreement may be terminated if not consummated by November 30, 2024, or December 31, 2024 (if SEC delays occur), or upon failure to obtain stockholder or regulatory approvals.
- Risks: Key risks include failure to meet closing conditions, disruption of operations, inability to list securities, and the success of Cyclo's clinical trials (specifically the TransportNPC trial).
- Lock-Up: Cyclo directors and affiliates are subject to a six-month lock-up agreement on Rafael shares received.
Investor Verification Checklist
- Verify the final exchange ratio and the specific valuation of Rafael's cash and marketable securities used in the calculation.
- Confirm the status of the Form S-4 registration statement and the scheduled dates for stockholder votes.
- Review the terms of the $3,000,000 convertible note, including conversion triggers and the 49.9% beneficial ownership limitation.
- Assess the progress of Cyclo's TransportNPC clinical trial and the sufficiency of Rafael's funding commitment to reach the 48-week interim analysis.
- Monitor for any regulatory actions or stockholder dissent that could trigger termination of the Merger Agreement.